Adjuvant lapatinib and trastuzumab for early human epidermal growth factor receptor 2-positive breast cancer: Results From the randomized phase III adjuvant lapatinib and/or trastuzumab treatment optimization trial

Martine Piccart-Gebhart, Eileen Holmes, Jośe Baselga, Evandro De Azambuja, Amylou C. Dueck, Giuseppe Viale, Jo Anne Zujewski, Aron Goldhirsch, Alison Armour, Kathleen I. Pritchard, Ann E. McCullough, Stella Dolci, Eleanor McFadden, Andrew P. Holmes, Liu Tonghua, Holger Eidtmann, Phuong Dinh, Serena Di Cosimo, Nadia Harbeck, Sergei TjulandinYoung Hyuck Im, Chiun Sheng Huang, Veronique Díeras, David W. Hillman, Antonio C. Wolff, Christian Jackisch, Istvan Lang, Michael Untch, Ian Smith, Frances Boyle, Binghe Xu, Henry Gomez, Thomas Suter, Richard D. Gelber, Edith A. Perez

Research output: Contribution to journal › Article › peer-review

231 Scopus citations

Fingerprint

Dive into the research topics of 'Adjuvant lapatinib and trastuzumab for early human epidermal growth factor receptor 2-positive breast cancer: Results From the randomized phase III adjuvant lapatinib and/or trastuzumab treatment optimization trial'. Together they form a unique fingerprint.

Medicine & Life Sciences